Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
HPLC was used to study the effectiveness of two different desferrioxamine (DFO) administration strategies (15 mg/kg DFO, 1 h or 44 h before dialysis) on generation of aluminoxamine and ferrioxamine in five hemodialysis patients. The percentage of ultrafilterable aluminum and iron in these patients was also investigated by electrothermal atomic absorption spectrometry. The administration of DFO in both schemes increased the ultrafilterable serum aluminum concentrations from a mean of 17.1 +/- 1.6% to a mean of 75.7 +/- 14.1%. However, 1 h after DFO infusion, only 38.8 +/- 7.7% of the total serum aluminum was bound to DFO; 44 h after DFO infusion, only 15.8 +/- 8.0% was bound. Similar results were obtained for ferrioxamine. These results suggest that the ultrafilterable serum fraction contains aluminum and iron chelated by DFO and by DFO metabolites, which retain similar metal-chelating abilities.
Menéndez-Fraga
P
P
Bone and Mineral Research Unit, Hospital Central de Asturias, Instituto Reina Sofía de Investigación Nefrológica, Oviedo, Spain.
Fernández-Martín
J L
JL
Blanco-González
E
E
Cannata-Andía
J B
JB
D000535:Aluminum / Q000097:blood*; D002614:Chelating Agents / Q000008:administration & dosage; D002851:Chromatography, High Pressure Liquid; D003676:Deferoxamine / Q000008:administration & dosage / Q000097:blood*; D005290:Ferric Compounds / Q000097:blood*; D006801:Humans; D009942:Organometallic Compounds / Q000097:blood*; D006435:Renal Dialysis; D013054:Spectrophotometry, Atomic; D013997:Time Factors; D014511:Uremia / Q000097:blood* / Q000628:therapy
D002614:Chelating Agents; D005290:Ferric Compounds; D009942:Organometallic Compounds; C002577:ferrioxamine B; C049544:aluminoxamine; D000535:Aluminum; D003676:Deferoxamine